Larry Heaton on insider trading restrictions
From Zomedica Q1 2026 Earnings Call | PulseVet and TRUFORMA Diagnostic Equipment Placements Expand · · Investing 101
“It means that there are things that as we move forward it will become more probable than not that certain material things that are known to me would not be and not known to shareholders would be likely to occur.”
On , Larry Heaton, President, Chief Executive Officer & Director at Zomedica, spoke about insider trading restrictions during Zomedica Q1 2026 Earnings Call | PulseVet and TRUFORMA Diagnostic Equipment Placements Expand on Investing 101.
About Larry Heaton
Larry Heaton, President, CEO, and Director of Zomedica, discussed the company's first quarter 2026 financial results during a May 29 earnings call. He reported $8.8 million in revenue, a 35% year-over-year increase, and noted that this marked the 21st consecutive quarter of record revenue growth. Heaton described surpassing $8 million in first-quarter revenue for the first time as a meaningful milestone, given that the first quarter has historically been the lowest revenue period seasonally. Heaton stated that the company's priorities include accelerating global adoption of its product portfolio, expanding recurring revenue streams, and progressing toward cash flow break-even and profitability, with a goal of achieving both in 2027. He also said that Zomedica would not engage in a stock buyback until it is cash flow positive, and that a long-term plan to reduce the number of shares outstanding would involve shareholder support. Heaton added that certain material developments known to him but not to shareholders may become more probable as the company moves forward.